en · de · es · fr · pt
cjc-1295-notes.peptides6608.com › Topic › Structure And Receptor Pharmacology — What the Evidence Shows

Structure And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2025-08-17 · last reviewed 2025-10-03 · Topic

DAC linker comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Related pages on this site

Persistence, Stability and Measurement

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.

Mechanism and Pharmacokinetics

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Notes from published material

=== CANOPUS: Compound class prediction === CANOPUS is short for class assignment and ontology prediction using mass spectrometry. It predicts the compound classes from the molecular fingerprint predicted by CSI:FingerID. This approach is completely database-free, i.e. it is not even limited to molecules that are listed in structure databases. CANOPUS employs a deep neural network (DNN) to predict 2,497 compound classes. The DNN was trained on 4.10 million compound structures with compound classes assigned by ClassyFire. No MS/MS data was used for training, but instead simulated 'realistic' probabilistic fingerprints for the training molecular structures were used. The DNN predicts all compound classes simultaneously. For full biological datasets, CANOPUS provides a comprehensive overview of compound classes present in the sample and allows for comparisons between different cohorts at compound class level.

However, the Center does not count itself as and is not perceived to be a think tank in the contemporary sense. During the 1960s, the phrase "think tank" was attached more broadly to meetings of experts, electronic computers, and independent military planning organizations. The prototype and most prominent example of the third category was the RAND Corporation, which was founded in 1946 as an offshoot of Douglas Aircraft and became an independent corporation in 1948. In the 1970s, the phrase became more specifically defined in terms of RAND and others. During the 1980s and 1990s, the phrase evolved again to arrive at its broader contemporary meaning of an independent public policy research institute. For most of the 20th century, such institutes were found primarily in the United States, along with much smaller numbers in Canada, the United Kingdom, and Western Europe. Although think tanks had also existed in Japan for some time, they generally lacked independence, having close associations with government ministries or corporations. There has been a veritable proliferation of "think tanks" around the world that began during the 1980s as a result of globalization, the end of the Cold War, and the emergence of transnational problems. Two-thirds of all the think tanks that exist today were established after 1970 and more than half were established since 1980.

In Las Delicias, Caquetá, five FARC fronts (about 400 guerrillas) recognized intelligence pitfalls in a Colombian Army base and exploited them to overrun it on August 30, 1996: killing 34 soldiers, wounding 17, and taking some 60 as prisoners. Another significant attack took place in El Billar, Caquetá on March 2, 1998 where a Colombian Army counterinsurgency battalion was patrolling, resulting in the death of 62 soldiers and the capture of some 43. Other FARC attacks against police bases in Miraflores, Guaviare and La Uribe, Meta in August 1998 killed more than a hundred soldiers, policemen, and civilians, and resulted in the capture or kidnapping of a hundred more. These attacks, and the dozens of members of the Colombian security forces taken prisoner by the FARC, contributed to increasingly shaming of the government of President Ernesto Samper Pizano (1994–1998) in the sectors of public and political opinion. He was already the target of numerous critics due to revelations of a drug-money scandal surrounding his presidential campaign. Perceptions of corruption due to similar scandals led to Colombia's decertification as a country cooperating with the United States in the war on drugs in 1995 (when the effects of the measure were temporarily waived), 1996, and 1997.

Sources: en.wikipedia.org

Further detail

=== Solubility === The solubility of mitragynine from kratom in neutral-pH and alkaline water is very low (0.0187 mg/ml at pH 9). The solubility of mitragynine in acidic water is higher (3.5 mg/ml at pH 4), however, this alkaloid can become unstable, so certain products, such as low-pH beverages, have a very short shelf life. Many vendors offer concentrated kratom products with claims of improved mitragynine solubility, however, those products are often formulated with solvents such as propylene glycol, which can make products unpleasant.

Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types. After GlaxoSmithKline received final FDA approval for topotecan on 15 October 2007, it became the first topoisomerase I inhibitor for oral use.

This experiment begun by observing that dialyzed (purified) yeast juice could not ferment or even create a sugar phosphate. This mixture was rescued with the addition of undialyzed yeast extract that had been boiled. Boiling the yeast extract renders all proteins inactive (as it denatures them). The ability of boiled extract plus dialyzed juice to complete fermentation suggests that the cofactors were non-protein in character.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

Is this compound a naturally occurring hormone?

No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.

Network